menu
    • menu

    Company profile for OrphoMed

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OrphoMed is a clinical-stage company with a proprietary dimer therapeutics platform. Our current focus is on developing therapies for irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OrphoMedUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    50 Francisco Street, Suite 245 San Francisco, CA 94133
    Telephone
    Telephone
    (415) 569-4417
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.orphomed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OrphoMed Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose
    OrphoMed Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose

    04 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220104005301/en

    BUSINESSWIRE
    04 Jan 2022
    Share Share
    OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2
    OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2

    14 Apr 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210414005035/en/OrphoMed%E2%80%99s-ORP-101-Passes-Second-Planned-Interim-Analysis-in-Phase-2-Study-of-Treatment-for-IBS-D-Patients

    BUSINESSWIRE
    14 Apr 2021
    Share Share
    OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D
    OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D

    26 Jan 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210126005028/en/OrphoMed-Passes-First-Interim-Analysis-in-Phase-2-Study-of-Treatment-for-IBS-D-Patients

    BUSINESSWIRE
    26 Jan 2021
    Share Share
    OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101
    OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101

    02 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200602005002/en

    BUSINESSWIRE
    02 Jun 2020
    Share Share
    OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020
    OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020

    19 Feb 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200219005113/en/OrphoMed-Present-Phase-1-Results-ORP-101-Digestive/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    19 Feb 2020
    Share Share
    OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020
    OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020

    19 Feb 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200219005113/en

    BUSINESSWIRE
    19 Feb 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search